>Posurdex/Lucentis combo. It's debatable whether SRDX should follow suit with a similar trial using I-vation.<
What is the debate? If the I-vation monotherapy results look good this fall, I don’t see why SRDX wouldn’t benefit by running a small combination trial with less-frequent Lucentis dosing.
Market Data 
Markets 
AI
